Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

RCT (n=4744) reports dapagliflozin had only a small effect on systolic blood pressure (SBP) in patients with heart failure & reduced ejection fraction and was superior to placebo in improving outcomes (worsening heart failure or cardiovascular death).

SPS commentary:

Authors’ of a related editorial suggest this new evidence may help to dissipate concerns about hypotension, which often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction – for whom poor outcomes are often attributed to low cardiac output and worse haemodynamic status associate with low SBP.

European Heart Journal

Resource links:

Editorial